Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China
By Pingzheng Mo, Y. Xing, Yu Xiao, Liping Deng, Qiu Zhao, Hongling Wang, Y. Xiong, Zhenshun Cheng, Shi-cheng Gao, K. Liang and 9 more. Clinical Infectious Diseases, 2020
881 citations recorded by the source corpus.
Abstract Background Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. This study aimed to clarify the characteristics of patients with refractory COVID-19. Methods In this retrospective single-center study, we included 155 consecutive patients with confirmed COVID-19 in Zhongnan Hospital of Wuhan University from January 1st to February 5th. The cases were divided into general and refractory COVID-19 groups according to the clinical efficacy after hospitalization, and the difference between groups were compared. Results Compared with general COVID-19 patients (45.2%), refractory patients had an older age, male sex, more underlying comorbidities, lower incidence of fever, higher levels of maximum temperature among fever cases, higher incidence of breath shortness and anorexia, severer disease assessment on admission, high levels of neutrophil, aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and C-reactive protein, lower levels of platelets and albumin, and higher incidence of bilateral pneumonia and pleural effusion (P<0.05). Refractory COVID-19 patients were more likely to receive oxygen, mechanical ventilation, expectorant, and adjunctive treatment including corticosteroid, antiviral drugs and immune enhancer (P<0.05). After adjustment, those with refractory COVID-19 were also more likely to have a male sex and manifestations of anorexia and fever on admission, and receive oxygen, expectorant and adjunctive agents (P<0.05) when considering the factors of disease severity on admission, mechanical ventilation, and ICU transfer. Conclusion Nearly 50% COVID-19 patients could not reach obvious clinical and radiological remission within 10 days after hospitalization. The patients with male sex, anorexia and no fever on admission predicted poor efficacy.
Subfields: Dermatology, Infectious Diseases, Neurology
View Paper: https://www.semanticscholar.org/paper/f13930556b21b44ecfdcda0fe700328c26810c15
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Smoking Is Associated With COVID-19 Progression: A Meta-analysis (2020, neutral): “Five studies 8 10 12 14 17 assessed whether the patient was a “current smoker,” three studies 9 16 19 assessed whether the patient was a current or former smoker (as separate categories), and four studies 11 13 15 18 assessed whether the patent had a “history of smoking” (current or former).”
- Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia (2020, background): “In December 2019, several cases of pneumonia of unknown origins were reported in Wuhan, Hubei Province, China [1, 2].”
- Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis (2020, neutral): “Mo P [61] 16-Mar-20 32173725 Single centre in Wuhan, Hubei Province, China 9”
- Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis (2020, background): “Most of the studies that reported COPD severity defined severe cases as those who were admitted to intensive care unit (ICU), had severe oxygenation, needed mechanical ventilation or death [18, 19, 22, 23, 27, 29].”
- Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. (2020, background): “Hospital length of stay, median (IQR), d NA 16 (11-22) NA”
- Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis (2020, methodology): “Finally, a total of 13 studies with 3027 patients were included [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] ( Figure 1 ).All of the selected studies were published in 2020 with different sample patient sizes that ranged from 27 to 1099 patients.”